Y mAbs Therapeutics Inc (YMAB) Actualités

Form 8-K - Current report

Correcting & Replacing – Y-mAbs Provides Strategic Business Update and 2025 Priorities

Company establishes two business units with goal of accelerating clinical development of its Radiopharmaceutical...

Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit

NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq:...

Y-mAbs Provides Strategic Business Update and 2025 Priorities

Company establishes two business units with goal of accelerating the advancement of its Radiopharmaceuticals...

Y-mAbs to Present at the 43rd Annual J.P. Morgan Healthcare Conference

NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq:...

Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting

NEW YORK, Dec. 07, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq:...

Y-mAbs to Participate at Citi’s 2024 Global Healthcare Conference

NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq:...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate Developments

Reported Total DANYELZA net product revenues of $18.5 million for the third quarter of 2024Entered into...

Form 8-K - Current report

Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) in Japan

NEW YORK, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq:...

Y-mAbs Announces Third Quarter 2024 Conference Call and Webcast

NEW YORK, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq:...

Y-mAbs to Participate in Upcoming Investor Conferences in October

NEW YORK, Oct. 01, 2024 (GLOBE NEWSWIRE) --  Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq:...